Mar 6, 2026 04:10PM
Mar 2, 2026 08:04AM
Mar 2, 2026 08:00AM
Feb 27, 2026 08:30AM
Feb 24, 2026 04:05PM
Feb 23, 2026 08:00AM
Feb 4, 2026 08:00AM UroGen Pharma to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit
Jan 5, 2026 08:00AM
Dec 22, 2025 07:06AM
Dec 5, 2025 08:00AM
Nov 6, 2025 08:00AM
Nov 6, 2025 07:58AM
Nov 6, 2025 07:58AM
Nov 4, 2025 08:00AM UroGen Pharma to Present at Guggenheim Securities Healthcare Innovation Conference
Oct 30, 2025 08:00AM
Oct 27, 2025 08:00AM
Oct 24, 2025 08:29AM
Oct 2, 2025 08:02AM
Oct 2, 2025 08:00AM
Sep 8, 2025 08:00AM
Aug 21, 2025 08:00AM UroGen Pharma to Present at Upcoming Investor Conferences
Aug 19, 2025 06:18AM
Aug 7, 2025 08:00AM
Aug 5, 2025 08:00AM
Aug 5, 2025 08:00AM
Jul 29, 2025 08:00AM
Jul 28, 2025 08:00AM
Jul 28, 2025 08:00AM UroGen Announces Publication of Phase 3b Study Results Demonstrating the Feasibility of Home Instillation of ZUSDURI™ for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer in
Jul 21, 2025 08:05AM
Jul 21, 2025 08:00AM
Jul 8, 2025 06:50AM
Jul 7, 2025 08:04AM
Jul 7, 2025 08:00AM
Jul 6, 2025 10:00AM
Jul 1, 2025 10:00AM INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UroGen Pharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - URGN
Jun 28, 2025 10:00AM
Jun 23, 2025 11:07AM
Jun 18, 2025 11:21AM
Jun 16, 2025 06:34AM
Jun 15, 2025 10:41PM
Jun 15, 2025 10:00AM
Jun 15, 2025 06:07AM URGN SHAREHOLDER NOTICE: BFA Law Alerts UroGen Pharma Ltd. Investors to Contact the Firm before Expiration of July 28 Class Action Deadline
Jun 13, 2025 03:10PM
Jun 13, 2025 10:30AM
Jun 13, 2025 07:46AM
Jun 13, 2025 07:17AM
Jun 13, 2025 07:16AM
Jun 12, 2025 04:00PM
Jun 12, 2025 01:28PM UroGen Pharma (URGN) Announces FDA Approval of ZUSDURI for Intravesical Solution as the First and Only Medication for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
Jun 12, 2025 01:28PM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All